Geron (NASDAQ:GERN) Shares Up 16.4% – Here’s What Happened

Shares of Geron Corporation (NASDAQ:GERN) traded up 16.4% during mid-day trading on Wednesday . The stock traded as high as $1.57 and last traded at $1.5601. Approximately 5,147,542 shares traded hands during trading, a decline of 66% from the average daily volume of 14,925,009 shares. The stock had previously closed at $1.34.

More Geron News

Here are the key news stories impacting Geron this week:

• Positive Sentiment: Geron reported second-quarter revenue of $57.48 million, exceeding analysts’ $55.30 million estimate, as sales of its Rytelo treatment reached a record level. The revenue beat helped support an initial positive reaction in the shares. Geron adds a record 16% as Rytelo drives Q2 revenue beat
• Positive Sentiment: Trading activity suggests some speculative optimism: investors purchased a large volume of Geron call options, potentially reflecting expectations for additional upside or favorable clinical and commercial developments. Stock Traders Buy Large Volume of Geron Call Options
• Neutral Sentiment: Analyst views on Geron and other healthcare stocks are mixed, indicating that Rytelo’s revenue growth is being balanced against continued profitability and execution risks. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Geron’s second-quarter EPS of $(0.02) missed the $(0.01) consensus estimate, underscoring that the company remains unprofitable despite stronger revenue. Geron: Q2 Earnings Snapshot
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across FY2027–FY2030, including FY2028 to $0.12 from $0.16 and FY2030 to $0.55 from $0.59. It also cut its FY2026 forecast to a $(0.05) loss from $(0.02), signaling more cautious expectations for Geron’s path to profitability.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Stock Performance

The company has a quick ratio of 4.96, a current ratio of 6.78 and a debt-to-equity ratio of 0.52. The stock has a 50 day simple moving average of $1.34 and a 200 day simple moving average of $1.46. The company has a market capitalization of $965.49 million, a price-to-earnings ratio of -13.68 and a beta of 0.61.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The company had revenue of $57.48 million for the quarter, compared to analyst estimates of $55.30 million. Geron had a negative return on equity of 24.06% and a negative net margin of 34.17%. As a group, analysts anticipate that Geron Corporation will post -0.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Geron

Large investors have recently added to or reduced their stakes in the stock. Eversept Partners LP increased its position in Geron by 6.7% in the 1st quarter. Eversept Partners LP now owns 18,834,883 shares of the biopharmaceutical company’s stock valued at $28,064,000 after acquiring an additional 1,174,900 shares during the period. Candriam S.C.A. boosted its position in Geron by 38.1% during the 1st quarter. Candriam S.C.A. now owns 3,921,476 shares of the biopharmaceutical company’s stock worth $5,843,000 after acquiring an additional 1,081,992 shares during the period. Vanguard Group Inc. boosted its position in Geron by 3.6% during the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock worth $47,072,000 after acquiring an additional 1,237,844 shares during the period. Seven Fleet Capital Management LP acquired a new position in Geron during the 4th quarter worth $1,027,000. Finally, 55 North Private Wealth LLC bought a new position in shares of Geron in the fourth quarter worth $29,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.